News

Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.

Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.

Todd Schlesinger, MD, reviews new photodynamic and adjuvant immunotherapy options for keratinocyte carcinoma, plus pipeline therapies and exosome research.

The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.

Chance, biology, and shared genetics may explain more small for gestational age births after living kidney donation.

Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.

A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.

Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.

Christoph Correll, MD, discusses how once-monthly subcutaneous olanzapine fills an LAI gap and why continuous coverage matters in schizophrenia.

Participants described how payer requirements and documentation of steroid exposure shape biologic access.

In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.

Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.

An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.

Calcified vessels may mask PAD on ankle brachial index testing, and Garimella says nephrologists can help catch it earlier.

Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.

Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.

Final VISIONARY data show sibeprenlimab held eGFR steady over 24 months, with a 4.5 mL/min/1.73 m² per year slope advantage and fewer kidney outcome events vs placebo.

Jonathan Barratt, PhD, FRCP, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack final ORIGIN 3 eGFR data for atacicept in IgAN.

In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.

For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.

The 150 mg once-daily pellet formulation gives patients aged ≥ 12 years a capsule alternative for HAE prophylaxis.

Amit X. Garg, MD, PhD, discusses new JAMA data on preeclampsia risk after living kidney donation in a 3-part video interview.

Fabiano Cavalcante, MD, discusses his secondary analysis of the DISTAL trial, which revealed minimal association between IVT and the effect of EVT in MDVO strokes.